Objective To determine the efficacy of photodynamic ther-apy(PDT)with verteporfin as a treatment for s ymptomatic polypoidal choroidal vasculopathy(PCV).Design Prospective consecutive,2-centered,noncomparative in-terventional case series.Particip ants Twenty-one Asian patients with 22eyes presenting with serosanguinous maculopathy due to PCV and an initial best-corrected vi-sual acuity(BCVA)of 20/40or worse were recruited prospectively.All patients had angiographic leakage seen on fluorescein angiograms (FAs )and features of PCVseen with indocyanine green(ICG)angiography.Methods In-travenous infusion of verteporfin a t a dose of 6mg /m 2 of body surface area over 10minutes was administered.Five minutes after the completion of infu sion,a 689-nm laser was applied for 83seconds,with a lig ht dose of 50J /cm 2 .The laser spot size was chosen to cover the polyps and the surrounding abnormally dilated choroidal vessels shown on ICG angiography plus an extra 1000-μm margin.Photo-dynamic therapy retreatment was performed if leakage from the polyps was found on both repeat FA s and ICG an-giography at regular 3-month follow-up intervals.Main outcome measures The proportion of e yes with stable or improved vision at a 1-year follow-u p.Secondary outcome measures included change in mean BCV A and the changes in clinical and angiographic featur es in FAs and ICG an-giography.The total number of PDT se ssions and any complications were also recorded.R esults Stable or im-proved vision was achieved in 21(95%)of the 22eyes at the 1-year follow-up.Ten(45%)eyes had a moderate gain in vision(improved by≥3lines),whereas 1(5%)eye suffered a moderate visual loss(decrease by≥3lines).The mean BCVA improved from a logarithm of the minimum angle of resolution(logMAR)of 0.73to 0.60,an equivalent of 1.3lines of improvement.The change in logMAR BCVA at 12months was statisti cally significant (Wilcoxon signed-ranks test,P=0.009).Complete ab-sence of leakage in FAs and total regression of the polyps in ICG angiography were observed in 20(91%)and 21(95%)eyes,respectively.Severe loss of v ision due to massive subretinal hemorrhage occu rred in 1eye;other-wise,there were no other serious tre atment-related adverse events.Conclusions The 1-year resu lts of PDT in treating PCV of the macular type with serosanguinous presentations are encouraging.Further studies wi th longer follow-up and randomized controlled trials are wa rranted to assess the long-term safety and efficacy of PDT relative to observation or other treatment modalities. Objective To determine the efficacy of photodynamic ther-apy (PDT) with verteporfin as a treatment for s ymptomatic polypoidal choroidal vasculopathy (PCV). Design Prospective consecutive, 2-centered, noncomparative in-terventional case series. Part- with 22 eyes presenting with serosanguinous maculopathy due to PCV and an initial best-corrected vi-sual acuity (BCVA) of 20 / 40or worse were recruited prospectively. All patients had angiographic leakage seen on fluorescein angiograms (FAs) and features of PCVseen with indocyanine green (ICG) angiography. Methods In-travenous infusion of verteporfin ata dose of 6 mg / m 2 of body surface area over 10 minutes was administered. Five minutes after the completion of infu sion, a 689-nm laser was applied for 83 seconds with a lig ht dose of 50 J / cm 2. The laser spot size was chosen to cover the polyps and the surrounding abnormally dilated choroidal vessels shown on ICG angiography plus an extra 1000-μm margin. Photo-dynamic the rapy retreatment was performed if leakage from the polyps was found on both repeat FA s and ICG an-giography at regular 3-month follow-up intervals. Main outcome measures The proportion of e yes with stable or improved vision at a 1-year follow -u p.Secondary measure of measure included change in mean BCV A and the changes in clinical and angiographic featur es in FAs and ICG an-giography. The total number of PDT se ssions and any complications were also recorded. Results of Stable or im- proved vision was achieved in 21 (95%) of the 22eyes at the 1-year follow-up.Ten (45%) eyes had a moderate gain in vision (improved by≥3lines), but 1 (5%) eye suffered a moderate mean loss (decrease by ≧ 3lines). The mean BCVA improved from a logarithm of the minimum angle of resolution (logMAR) of 0.73 to 0.60, an equivalent of 1.3lines of improvement. change in log MAR BCVA at 12 months was was statisti cally significant (Wilcoxon signed-ranks test, P = 0.009) .Complete ab-sence of leakage in FAs and total regression of the polyps in ICG angiography were observed in 20 (91%) and 21 (95%) eyes, respectively. Severe loss of v ision due to massive subretinal hemorrhage occu rred in 1eye; other-wise, there were no other serious trement-related adverse events. Conclusions The 1-year resu lts of PDT in treating PCV of the macular type with serosanguinous presentations are encouraged. Faculty studies wi th longer follow-up and randomized controlled trials are wa rranted to assess the long-term safety and efficacy of PDT relative to observation or other treatment modalities.